-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Upgrades ImmunityBio to Overweight, Raises Price Target to $5

Benzinga·05/20/2025 13:58:59
Listen to the news
Piper Sandler analyst Joseph Catanzaro upgrades ImmunityBio (NASDAQ:IBRX) from Neutral to Overweight and raises the price target from $4.25 to $5.